Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies (Details Narrative)

v3.8.0.1
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Number of shares acquired in exchange for common stock     2,090,301  
Common stock issued     35,272,626   35,272,626
Common stock shares outstanding     35,272,626   35,272,626
Accumulated deficit     $ (4,955,884)   $ (3,859,086)
Net loss from continuing operations     1,100,000    
Net cash used in operating activities from continuing operations     (1,069,008) $ (58,698)  
Cash and cash equivalents     1,776,639 1,012,314 2,847,429
Money market funds     961,193   $ 1,300,815
Impairment of long lived assets      
Lease expire date     Sep. 30, 2019    
CoNCERT Pharmaceuticals, Inc [Member]          
Number of shares acquired in exchange for common stock 2,090,301        
Precentage of issued and outstanding common stock diluted basis 5.93%        
Option exercised in exchange for common stock $ 8,000,000        
Percentage of common stock holdings 6.58%        
Percentage of royalty 15.00%        
Proceeds from royalty receivable $ 8,000,000        
Controlling interest, description Promet’s controlling interest was reduced from 90% to 84%.        
CoNCERT Pharmaceuticals, Inc [Member] | Additional Paid-In Capital [Member]          
Proceeds from royalty receivable $ 8,000,000        
Parent Company [Member]          
Number of shares acquired in exchange for common stock   31,745,242      
Precentage of issued and outstanding common stock diluted basis   90.00%      
Common stock issued     35,272,626    
Common stock shares outstanding     35,272,626    
Parent Company [Member] | CoNCERT Pharmaceuticals, Inc [Member] | Option and License Agreement [Member]          
Number of shares acquired in exchange for common stock 2,090,301        
Precentage of issued and outstanding common stock diluted basis 5.93%        
Option exercised in exchange for common stock $ 8,000,000        
Percentage of common stock holdings 6.58%        
Percentage of royalty 15.00%        
Proceeds from royalty receivable $ 8,000,000        
Controlling interest, description Promet’s controlling interest in Processa was reduced from 90% to 84%.        
Parent Company [Member] | CoNCERT Pharmaceuticals, Inc [Member] | Option and License Agreement [Member] | Additional Paid-In Capital [Member]          
Proceeds from royalty receivable $ 8,000,000